Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion

Paclitaxel, a new antitubular agent, appears to be one of the most promising single agents for the chemotherapy of various solid tumors. The primary objectives of this phase I study of paclitaxel using 24‐h continuous intravenous infusions were to determine the maximum tolerated dose of paclitaxel a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Tomohide, Sasaki, Yasutsuna, Eguchi, Kenji, Shinkai, Tetsu, Ohe, Yuichiro, Nishio, Makoto, Kunikane, Hiroshi, Arioka, Hitoshi, Karato, Atsuya, Omatsu, Hironobu, Nakashima, Hajime, Saijo, Nagahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1994
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919347/
https://www.ncbi.nlm.nih.gov/pubmed/7961108
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02906.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919347/
https://www.ncbi.nlm.nih.gov/pubmed/7961108
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02906.x

Ejemplares similares